Physician Payments Sunshine Act: Review of Individual State …
Apr 2, 2014 · The Physician Payments Sunshine Act gets most of the attention on Policy & Medicine these days with phase I submitted and other important deadlines looming. However, a number of states have aggregate spend requirements that will not be preempted by the Federal Sunshine Act. We recently reported on Washington DC’s annual transparency report, and have paid close attention to Vermont’s ...
Market Research and the Physician Payments Sunshine Act: Has …
Feb 23, 2015 · The market research space is an interesting one as far as Sunshine reporting is concerned because it implicates many of the same challenging “indirect payment” issues we have seen related to continuing medical education (CME). This article desc
Open Payments – Policy & Medicine
With little fanfare on June 30th, the Centers for Medicare & Medicaid Services (CMS) published Program Year (PY) 2022 Open…
French Sunshine Act: Public Database Published
May 28, 2014 · As we’ve said a lot this year, transparency is a global phenomenon.The Loi Bertrand, or the French Sunshine Act, is similar in many ways to the US Physician Payments Sunshine Act, but even more expansive.These differences pose significant hurdles for companies attempting to build uniform programs to comply with these laws.
FDA and Disease Awareness Programs – Policy & Medicine
Aug 5, 2010 · – Perceptual distinctiveness in terms of thematic, graphic, visual and other presentation elements is “determinant issue;” With regards to one product companies, Friede noted that such companies are not automatically disqualified from disease awareness communications, but instead face heightened scrutiny.
Physician Payment Sunshine Act Final Rule: Research
Feb 5, 2013 · Under the Physician Payment Sunshine Act Final Rule, certain research payments or other transfers of value made to a covered recipient by an applicable manufacturer under a product research or development agreement may be delayed from publication on the website. “This provision seeks to balance the need for confidentiality of proprietary information with the need for public transparency of ...
Modern Medicine vs. Alternative Medicine: Different Levels of …
Aug 16, 2011 · The web page compares the benefits and drawbacks of modern medicine and alternative medicine, citing statistics, examples, and arguments from both sides. It also discusses the challenges and controversies of integrating alternative medicine with mainstream medicine.
DEA and HHS Extend Telehealth Flexibilities for Controlled …
Jan 10, 2024 · The DEA and the HHS announced they will extend pandemic-era telehealth prescribing flexibilities for controlled substances through 2024. The rule ensures a smooth transition for patients and practitioners, while the DEA works to write new regulations and revise its proposed final rule.
Anti-Kickback Alert: Pharmaceutical Manufacturer Copayment …
Sep 23, 2014 · OIG also criticized the size and placement of the notice of eligibility on individual co-pay cards. “In some instances, notices to beneficiaries, particularly those downloaded and printed from the Internet, are on pages following the coupons and not on the coupons themselves,” OIG notes.
Biden Administration Rescinds Trump Administration Insulin …
Oct 26, 2021 · The Trump Administration finalized a rule in December 2020 that directed HHS to require FQHCs to offer insulin and injectable epinephrine at 340B prices to certain patients. The Biden Administration rescinded the rule in October 2021, citing excessive administrative costs and burdens for health centers.